We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-20.83%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$803M
AUM Growth
-$319M
Cap. Flow
-$34M
Cap. Flow %
-4.24%
Top 10 Hldgs %
60.78%
Holding
78
New
17
Increased
17
Reduced
12
Closed
19

Top Buys

Rank Stock Value
1
NCNA
NuCana
NCNA
+$28.4M
2
GILD icon
Gilead Sciences
GILD
+$14.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.4M
4
INCY icon
Incyte
INCY
+$12.2M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.65M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$61.6M
2
AGN
Allergan plc
AGN
+$18.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.09M
4
APLS
Apellis Pharmaceuticals
APLS
+$7.67M
5
EXEL icon
Exelixis
EXEL
+$7.15M

Sector Composition

Rank Sector Weight
1 Healthcare 91.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.13B
$5.71M 0.71%
754,372
+56,147
+8% +$505K
DCPH
27
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.57M 0.69%
+265,475
New +$6.53M
ICPT
28
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.49M 0.68%
+54,472
New +$5.65M
SRPT icon
29
Sarepta Therapeutics
SRPT
$1.66B
$5.34M 0.66%
48,894
+18,979
+63% +$2.37M
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
$5.17M 0.64%
+287,769
New +$5.88M
CHMA
31
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.07M 0.63%
1,630,221
-136,881
-8% -$491K
ETTX
32
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$4.8M 0.6%
1,180,178
– –
NBIX icon
33
Neurocrine Biosciences
NBIX
$17.7B
$4.39M 0.55%
+61,500
New +$5.89M
MGNX icon
34
MacroGenics
MGNX
$235M
$4.23M 0.53%
+332,921
New +$5.58M
AIMT
35
DELISTED
Aimmune Therapeutics
AIMT
$4.21M 0.52%
175,775
-46,520
-21% -$1.2M
SYBX
36
DELISTED
Synlogic
SYBX
$4.03M 0.5%
38,331
– –
DERM
37
DELISTED
Dermira, Inc.
DERM
$3.9M 0.49%
542,224
+46,931
+9% +$513K
PBYI icon
38
Puma Biotechnology
PBYI
$406M
$3.88M 0.48%
190,627
-146,208
-43% -$4.39M
KYNB
39
Kyntra Bio
KYNB
$28.5M
$3.7M 0.46%
+3,200
New +$3.6M
BHVN
40
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.6M 0.45%
97,445
-35,621
-27% -$1.28M
ORTX
41
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.5M 0.44%
+22,262
New +$3.32M
EPZM
42
DELISTED
Epizyme, Inc
EPZM
$3.47M 0.43%
563,655
+272,337
+93% +$2.08M
KDMN
43
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.44M 0.43%
1,651,172
-191,330
-10% -$482K
FOMX
44
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.99M 0.37%
832,293
+163,674
+24% +$712K
FATE icon
45
Fate Therapeutics
FATE
$281M
$2.95M 0.37%
229,813
+124,922
+119% +$1.74M
FPRX
46
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.93M 0.37%
+315,344
New +$3.75M
GWPH
47
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.92M 0.36%
+30,000
New +$3.94M
KALA icon
48
KALA BIO
KALA
$11.8M
$2.18M 0.27%
178
+140
+368% +$2.43M
IMGN
49
DELISTED
Immunogen Inc
IMGN
$2.15M 0.27%
+447,075
New +$2.71M
RVLP
50
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$1.96M 0.24%
+253,089
New +$2.03M
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2018 Portfolio in Review

As of Q4 2018, Sofinnova Investments held 78 positions worth $803M, down 28% from $1.12B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sofinnova Investments withdrew a net $34M in Q4 2018, closing 19 positions and reducing 12 holdings. Its most notable exit was Allergan plc, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 86% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Gilead Sciences worth $13.3M.

  • Sofinnova Investments's largest Q4 2018 buy was Gilead Sciences: 213,331 shares worth $13.3M.
  • Sofinnova Investments added most to NuCana in Q4 2018, an estimated $28.4M increase.
  • Sofinnova Investments's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $61.6M.
  • Sofinnova Investments fully exited Allergan plc in Q4 2018, selling an estimated $18.3M.
  • Sofinnova Investments's ten largest holdings make up 61% of its $803M portfolio in Q4 2018.
  • Sofinnova Investments opened 17 new positions and closed 19 in Q4 2018.
  • Sofinnova Investments's portfolio value fell 28% quarter-over-quarter to $803M.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.